Drug Trial Radar · NCT07550621
Drug-Drug Interaction Study of MDR-001 With Rifampin and Itraconazole in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
28
Planned (sponsor's estimate)
Start
May 6, 2026
Primary completion
May 31, 2026
Study completion Jun 8, 2026
Sponsor
- Lead sponsor
- MindRank AI LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase I, open-label, fixed-sequence, two-part drug-drug interaction study in healthy Chinese adults to evaluate the effect of multiple-dose rifampin (Part A) or itraconazole (Part B) on the single-dose pharmacokinetics of MDR-001, an oral GLP-1 receptor agonist.
Conditions
- Healthy Volunteers (HV)
Interventions
MDR-001Drug
Oral small-molecule GLP-1 receptor agonist ;Investigational drug (not yet approved)
RifampinDrug
Strong CYP3A4 inducer; Marketed anti-tuberculosis drug
ItraconazoleDrug
Strong CYP3A4 inhibitor; Marketed antifungal drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax of MDR-001Time frame: Baseline (Day 1 pre-dose) and up to 48 hours post-dose on Day 1 and on co-administration (Day 10 for Part A, Day 7 for Part B).
- AUC0-t of MDR-001Time frame: Baseline (Day 1 pre-dose) and up to 48 hours post-dose on Day 1 and on co-administration (Day 10 for Part A, Day 7 for Part B).
- AUC0-∞ of MDR-001Time frame: Baseline (Day 1 pre-dose) and up to 48 hours post-dose on Day 1 and on co-administration (Day 10 for Part A, Day 7 for Part B).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Hospital of Jilin University
Changchun, Jilin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.